Therapeutic Management of COVID-19 Patients: A systematic review

Abstract

Background: SARS-CoV-2 is the cause of the COVID-19 that has been declared a global pandemic by the WHO in 2020. The COVID-19 treatment guidelines vary in each country, and yet there is no approved therapeutic for COVID-19. were included. The search terms included combinations of: COVID, SARS-COV-2, glucocorticoids, convalescent plasma, antiviral, antibacterial. There were no restrictions on the type of study design eligible for inclusion. Results:As of March 26, 2020, of the initial manuscripts identified (n=449) articles. Forty-one studies were included, of which clinical trials (n=3), (case reports n=7), case series (n=10), retrospective (n=11) and prospective (n=10) observational studies. Thirtysix studies were conducted in China (88%).The most common mentioned and reported medicine in this systematic review was corticosteroids (n=25), followed by Lopinavir (n=21) and oseltamivir (n=16).

Implications of COVID-19 in high burden countries for HIV/TB: A systematic review of evidence

“…Remdesivir should also not associate to rifampicin in COVID-19/TB co-infection because of strong induction [64]. A recent review has reported that chloroquine phosphate and hydroxychloroquine showed favorable outcomes in the recovery of COVID-19 patients [65][66][67][68][69]. Both chloroquine and hydroxychloroquine are metabolized by hepatic cytochrome P450 enzyme 2D6 (CYP2D6) [70].…”

“…A study showed an association between corticosteroid use and lower mortality in COVID-19 patients [69]. Using a glucocorticoid in the early stages of the prognosis for a brief period of time could minimize the in ammation, but longer-term use could result in the risk of HIV and/or TB activation and even lack of treatment with TB.…”

“…Using a glucocorticoid in the early stages of the prognosis for a brief period of time could minimize the in ammation, but longer-term use could result in the risk of HIV and/or TB activation and even lack of treatment with TB. Careful use of corticosteroids with low-to-moderate doses in short courses is advised [69]. Besides, brosis and extensive pulmonary pathology secondary to TB and COVID-19, as de ned in the introduction, can reduce drug penetration at the lung sites.…”

“…Besides, liver and kidneys toxicities related to severe and critical COVID-19 need a tailored therapeutic approaches in HIV/TB co-morbidities due to some hepatotoxicity and nephrotoxicity of some HIV/TB drugs such as streptomycin, isoniazid, rifampicin, pyrazinamide, tenofovir disoproxil, atazanavir/ritonavir, lopinavir/ritonavir as well as HIV induced nephropathy and hepatitis associated to HIV. [69]. Chloroquine: 1 gm PO once on Day 1, then 500 mg PO once daily for 4-7 days, hydroxychloroquine: 800 mg PO once on Day 1, then 400 mg PO once daily for 4-7 days [64] or lopinavir 400 mg/ritonavir 100 mg PO twice [65].…”

Maternal and perinatal outcomes and pharmacological management of Covid-19 infection in pregnancy: a systematic review protocol

“…Ever since the outbreak, the healthcare team and researchers across the globe have proposed several pharmacological interventions that could prove effective in treating COVID-19 (22). Various treatment options include, but are not limited to, antivirals and combinations, angiotensin receptor blockers, antimalarial, antihistamines, steroids, antipyretics (23).…”